TARSHIGH SIGNALFINANCIAL10-K

TARS demonstrated substantial operational improvement with meaningfully reduced operating cash burn while growing its balance sheet significantly through what appears to be equity financing.

The company's operating cash flow improved dramatically from -$83.0M to -$12.5M, indicating much better operational efficiency despite substantially higher SG&A expenses. The near-doubling of cash position alongside increased stockholders' equity suggests successful capital raising, providing financial runway for continued operations.

Comparing 2026-02-23 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

TARS showed strong financial momentum across key metrics, with cash nearly doubling to $183.6M and accounts receivable growing substantially, likely reflecting increased XDEMVY sales. While SG&A expenses grew meaningfully, the company achieved much improved cash flow performance, burning significantly less cash operationally. The overall picture suggests a biotechnology company successfully scaling its commercial operations while maintaining strong liquidity through strategic financing.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+93.7%
$94.8M→$183.6M

Cash position surged 93.7% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
+85%
-$83.0M→-$12.5M

Operating cash flow surged 85% — exceptional cash generation, highest quality earnings signal.

Accounts Receivable
Balance Sheet
+81.9%
$46.8M→$85.1M

Receivables surged 81.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

SG&A Expense
P&L
+80.1%
$237.3M→$427.3M

SG&A up 80.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+68.3%
$80.6M→$135.7M

Current liabilities surged 68.3% — significant near-term obligations; verify ability to meet short-term debt.

Inventory
Balance Sheet
+66.9%
$2.6M→$4.4M

Inventory surged 66.9% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Stockholders Equity
Balance Sheet
+53%
$224.5M→$343.4M

Equity base grew 53% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Interest Expense
P&L
+52.2%
$2.2M→$3.3M

Interest expense surged 52.2% — significant debt increase or rising rates materially impacting earnings.

Total Assets
Balance Sheet
+49.1%
$377.0M→$562.2M

Asset base grew 49.1% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+46.6%
$356.7M→$522.8M

Current assets grew 46.6% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-23
PRIOR — 2025-02-25
ADDED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
As of February 17, 2026, the number of outstanding shares of the registrant s common stock, par value $0.0001 per share, was 42,557,492 .
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 98 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 100 Item 7A.
We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.
While we have generated revenue from the launch of XDEMVY, we have continued to incur losses and negative cash flows from operations since our inception and anticipate that we could continue to incur significant expenses and potential losses in the future.
in July 2023 and commenced the commercial launch of XDEMVY in August 2023.
We have limited experience as a commercial company generating revenue from product sales.
If the commercialization of XDEMVY becomes unsuccessful or any future approved product launches are unsuccessful, our ability to become or remain profitable may be unsuccessful.
We may not ultimately be successful in educating Eye Care Professionals ( ECPs ), and the market about the need for treatments specifically for Demodex blepharitis and other diseases or conditions targeted by XDEMVY or our product candidates.
REMOVED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act.
As of February 19, 2025, the number of outstanding shares of the registrant s common stock, par value $0.0001 per share, was 38,377,178 .
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 96 Item 6.
Management's Discussion and Analysis of Financial Condition and Results of Operations 98 Item 7A.
We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.
While we have generated revenues from the launch of XDEMVY, we have continued to incur significant losses and negative cash flows from operations since our inception and anticipate that we will continue to incur significant expenses and potential losses for the foreseeable future.
in July 2023 and have limited experience as a commercial company generating revenue from product sales.
If the commercialization of XDEMVY becomes unsuccessful or any future approved product launches are unsuccessful, we may never be profitable.
We may not be successful in educating eye care providers ("ECPs"), and the market about the need for treatments specifically for Demodex blepharitis and other diseases or conditions targeted by XDEMVY or our product candidates.
The sizes of the market opportunity for XDEMVY for the treatment of Demodex blepharitis, as well as our other product or product candidates, have not been established with precision and may be smaller than we estimate, possibly materially.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →